Back to all studies
RecruitingNCT06706232

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolarity II Depression and Suicidality

This study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.

BipolarityDrugFrom 25 Years to 70 Years
In plain English

Key information made simple

This study is looking at whether questionnaires and follow-up can help people with Bipolarity II, Depression in bipolarity, or Suicidality. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to questionnaires and follow-up, but direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a university, with sites including The University of Texas Health Science Center at Houston. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include safety concerns that need urgent care first. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Public study data

Key study information

Official title
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Condition
Bipolar II Disorder; Depression, Bipolar; Suicidality
Study status
Recruiting
Phase
Phase 2
Sponsor / lead affiliation
The University of Texas Health Science Center, Houston
Intervention
Psilocybin, Therapeutic Support
Location / country
United States
Contact
Thomas Meyer, PhD, Lauren Vale, MA, Jair C. Soares, MD, PhD, Joao De Quevedo, MD, PhD
Email
thomas.d.meyer@uth.tmc.edu, lauren.n.vale@uth.tmc.edu
Phone
713-486-2643
Registry
ClinicalTrials.gov
Why this study may matter

Why this study may matter

This study may matter because it is evaluating Psilocybin, Therapeutic Support in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.

Before joining

Questions to ask before joining

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT06706232. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular follow-up, often through questionnaires or interviews.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
The University of Texas Health Science Center, Houston
Sponsor type
University
Main activity
medication or study treatment
Intervention
Psilocybin, Therapeutic Support
Time commitment
long follow-up or multiple visits
Study phase
Phase 2
Enrollment
Not available
Recruitment status
Recruiting
Source
Official registry link
FAQ

Questions about this study

What is Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolarity II Depression and Suicidality?

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by The University of Texas Health Science Center, Houston. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is Phase 2. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Acceptability & Safety of Two Sequential Doses of. — Bipolarity Clinical Trial | HopeStage